News|Articles|December 30, 2024

Our Top 5 Social Media Posts of 2024

Check out our top five most engaged social media posts from the year 2024.

1.

2.

3.

4.

5.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay

Our Top 5 Social Media Posts of 2024

1.

2.

3.

4.

5.

Related Content

How Realistic Project TrialBlazer’s Stated Goals Are

How Has The Strait of Hormuz Situation Shaped The API Innovation Center's Thinking About Geographic Diversification?

The Remaining Gaps in Employer-Covered GLP-1 Benefits

R&D Is Investing in AI, Just Not Where It Matters Most

Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons

Trending on PharmExec

Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay